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Human Beta-Defensin 3 Is Up-Regulated in Cutaneous
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Abstract
Background: Leprosy, a chronic granulomatous disease affecting the skin and nerves, is caused by Mycobacterium leprae (M.
leprae). The type of leprosy developed depends upon the host immune response. Type 1 reactions (T1Rs), that complicate
borderline and lepromatous leprosy, are due to an increase in cell-mediated immunity and manifest as nerve damage and
skin inflammation. Owing to the increase in inflammation in the skin of patients with T1Rs, we sought to investigate the
activation of the innate immune system during reactionary events. Specifically, we investigated the expression levels of
human beta-defensins (hBDs) 2 and 3 in the skin of patients with T1Rs, in keratinocytes, and in macrophages stimulated
with M. leprae and corticosteroids.
Results: Skin biopsies from twenty-three patients with Type 1 reactions were found to have higher transcript levels of hBD3
as compared to fifteen leprosy patients without Type 1 reactions, as measured by qPCR. Moreover, we observed that
keratinocytes but not macrophages up-regulated hBD2 and hBD3 in response to M. leprae stimulation in vitro.
Corticosteroid treatment of patients with T1Rs caused a suppression of hBD2 and hBD3 in skin biopsies, as measured by
qPCR. In vitro, corticosteroids suppressed M. leprae-dependent induction of hBD2 and hBD3 in keratinocytes.
Conclusions: This study demonstrates that hBD3 is induced in leprosy Type 1 Reactions and suppressed by corticosteroids.
Furthermore, our findings demonstrate that keratinocytes are responsive to M. leprae and lend support for additional
studies on keratinocyte innate immunity in leprosy and T1Rs.
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Introduction
Leprosy, caused by the pathogen Mycobacterium leprae (M. leprae),
is a chronic granulomatous infection that causes skin lesions and
potentially disabling neuropathy. Whilst the widespread use of
multi-drug therapy (MDT) has reduced the disease burden
globally, 213,036 new cases were reported in 2009 and leprosy
continues to be an important health concern especially in areas
such as India, Brazil, and Africa [1].
The clinical manifestations and classification of leprosy correlate
with the type of immune response generated by the host.
Tuberculoid leprosy (TT), on one pole of the spectrum, results
from patients having an intense cell-mediated immune response
and is characterized by an abundance of Th1 cytokines. On the
opposite end of the spectrum are the patients with lepromatous
leprosy (LL), characterized by a predominant humoral response
and lack of M. leprae-specific cell-mediated immunity [2]. Patients
with the borderline forms of leprosy fall between the two poles (TT
and LL), are immunologically unstable, and are more prone to
complicating reactions.
Type 1 reactions (T1Rs) correlated with an increase in Th1-
mediated immunity while Type 2 reactions (also known as
erythema nodosum leprosum, ENL) are associated with Th2
humoral complications. Reactions can occur in up to 30–50% of
leprosy patients as single or recurrent episodes anytime before,
during or years after effective multi-drug therapy (MDT). Due to
the lipid content of the cell wall, M. leprae infection can leave
behind persistent antigens within affected skin and nerve tissues
rendering patients vulnerable to unpredictable leprosy reactions
years after technical cure. Leprosy reactions, therefore, are a
major factor of permanent neuropathy and disability development
for patients. In response to the upgrades in cell-mediated
immunity, T1Rs are often treated using oral corticosteroids,
usually prednisolone. One of the effects of corticosteroids is the
suppression of skin inflammation (edema and erythema) associated
with cutaneous T1Rs.
Previous studies have suggested a prominent role for toll-like
receptor (TLR) 2 in susceptibility to infection by M. leprae and
Mycobacterium tuberculosis (Mtb). TLR2 is a receptor that recognizes
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pathogen associated molecular patterns (PAMPs); more specifical-
ly, these are diacylated and triacylated lipopetides that respectively
bind to the TLR2/6 and TLR2/1 heterodimeric complexes [3].
Mycobacteria produce triacylated lipopetides and thereby induce
immunological responses through the TLR2/1 complex [4].
TLR2/1 activation leads to the clearance of pathogens, such as
M. leprae or Mtb, by macrophages, neutrophils, and epithelial cells.
Several consequences of TLR2/1 activation are the production of
pro-inflammatory cytokines and antimicrobial peptides. In partic-
ular, TLR2 stimulation leads to induction of cathelicidin, and
human beta-defensins (hBDs) 2 and 3 in the epithelium and
macrophages [5]. These antimicrobial peptides serve as the first
line of defense against many bacteria, viruses, and fungi [6,7,8,9].
In addition to directly killing pathogens, hBD2 induces cytokines
including IL-6, IL-8, and IL-10 in monocytic cells [10].
Cell-specific studies on leprosy have predominantly focused on
dermal cells such as macrophages, neutrophils, and T cells. In the
dermis, macrophages are important cell types that promote Th1
responses. Macrophages are able to phagocytose and sequester
viable M. leprae in their phago-lysosomes [11]. In the epidermis,
keratinocytes are known to sense and eliminate pathogens by
activating TLR-mediated innate responses while also affecting the
dermal innate and adaptive immune responses. Although kerati-
nocytes have not been a focus in leprosy, electron microscopy
studies have in fact demonstrated M. leprae inside keratinocytes
[12]. Other studies have also demonstrated that M. leprae proteins
promote entry in keratinocytes [13] and induce MHCII in
keratinocytes [14]. These data suggest an important role for
keratinocytes in leprosy, as in other cutaneous infections.
Specifically, the antimicrobial role of keratinocytes in defense
has been previously demonstrated for cutaneous pathogens [15]
but is still being understood in leprosy.
As M. leprae cannot be grown in vitro and animal studies are
logistically challenging, genetic and in vitro infection studies have
been employed to understand the role of host immunological
factors in susceptibility to leprosy. One study demonstrates that M.
leprae activates the TLR2/1 heterodimeric complex in HEK 293
cells, and activation is enhanced by Th1 cytokines [4]. Another
study demonstrates that polymorphisms in hBD1 are associated
with lepromatous leprosy [16]. Other studies conclude that a
TLR2 mutation is associated with susceptibility to lepromatous
leprosy [17,18] and Type 1 reactions [19]. In support of the TLR2
polymorphic and mutation studies, in vitro mechanistic studies
suggest that a TLR2 mutation leads to attenuated production of
Th1 cytokines [20,21]. Although these genetic studies are
interesting and support an association of TLR2 in susceptibility
to leprosy and Type 1 reactions, they have few subjects.
Furthermore, the role of TLR2 activation in keratinocytes in
Type 1 reactions has not yet been fully elucidated.
Several other studies on TLRs, surface proteins, and mycobac-
terial lipids have been performed that further suggest the
importance of innate immunity in leprosy pathogenesis. TLR9
has been shown to mediate responses to mycobacterium [22,23].
Genetic studies also indicate that TLR4 and NOD2 polymor-
phisms are associated with susceptibility to leprosy [24]. In
addition, CD209 (DC-SIGN), a C-type lectin, allows for phago-
cytosis of M. leprae. This study further shows that the cytokine
environment of tuberculoid leprosy (IL-15) leads to an induction of
an antimicrobial program in macrophages in tuberculoid lesions
[25]. Collectively, these studies demonstrate that the immune
response in leprosy is both complex and diverse.
Here, we investigate the expression of hBD2 and hBD3 in the
skin of leprosy patients with Type 1 reactions using qPCR. These
skin biopsies were taken as part of a previous clinical trial on
corticosteroids [26]. Furthermore, we determine the expression
hBDs in M. leprae- treated keratinocytes and macrophages in vitro
using qPCR and immunoflourescence. Finally, we aim to
investigate whether corticosteroids suppress hBD expression in
the skin biopsies as well as in keratinocytes in vitro. These studies
will ideally lead to a greater understanding of the role of
keratinocytes in leprosy, in diagnostics, and in susceptibility to
infection by M. leprae.
Materials and Methods
Ethics statement
This study was approved by the Nepal Health Research Council
and the Ethics Committee of the London School of Hygiene and
Tropical Medicine (Number 4022). All subjects provided informed
written consent.
Skin biopsies
Full-thickness skin biopsies were taken from leprosy patients
with and without Type 1 Reactions at Anandaban Hospital in
Kathmandu, Nepal [26]. The case definitions and Ridley-Joplin
classifications for the patients with leprosy and Type 1 reactions in
this study have been previously published [26]. In a double blind
parallel-group randomized controlled trial (RCT), patients with
Type 1 reactions or nerve function impairment were randomized
to receive high dose intravenous methylprednisolone (MP)
followed by oral prednisolone or intravenous normal saline
followed by oral prednisolone. Control subjects were untreated
newly diagnosed leprosy patients who presented to Anandaban
Hospital during the period of recruitment and follow-up of the
methylprednisolone study. Biopsies from control subjects and
T1Rs subjects were stored in RNA Later (Sigma) until processing.
This study utilizes biopsies taken at day 0 (before corticosteroid
treatment) and day 113 (at the end of corticosteroid treatment).
We analyzed skin biopsies from 28 patients with T1Rs and 15
patients without T1Rs that served as controls. Of these 28 patients
with T1Rs, 23 patients received corticosteroid treatment (oral
prednisolone 6 intravenous methylprednisolone). Skin biopsies of
Author Summary
Leprosy, caused by Mycobacterium leprae (M. leprae), is a
chronic infection leading to potentially debilitating nerve
damage. Although the infection is curable with multi-drug
therapy, many patients continue to suffer from episodes of
inflammation, called Type 1 reactions. These reactions may
lead to nerve damage and deformation. Patients with Type
1 reactions are treated with corticosteroids to reduce the
inflammation. Elucidating the immune factors contributing
to leprosy Type 1 reactions will further clarify why many
leprosy patients develop nerve and skin inflammation. We
conducted a study to understand whether the antimicro-
bial peptides, human beta-defensins (hBD) 2 and 3, are
increased in the skin of leprosy patients with Type 1
reactions. We also investigated keratinocyte expression of
hBD2 and hBD3 in response to M. leprae. In this study, we
found that hBD3 was significantly increased in the skin of
leprosy patients with Type 1 reactions. Moreover, we
demonstrated that corticosteroid treatment reduced the
expression of hBD3 in patients with Type 1 reactions. We
also found that keratinocytes incubated with M. leprae up-
regulated hBD2 and hBD3 in vitro; corticosteroids were
found to suppress this response. These studies suggest a
role for the innate immune system in leprosy Type 1
reactions.
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these 23 patients (with T1Rs and receiving corticosteroid
treatment) were analyzed on day 0 and day 113, before and after
corticosteroid treatment, respectively. Cellular infiltration, the
relative abundance of infiltrated cells in the dermis (whose nuclei
stain with hematoxylin), was performed as previously described
[27].
Cell culture
A human keratinocyte cell line, (HaCaT cells), kindly supplied
by Dr. Edel O’Toole (St. Barts and The London), were
maintained in DMEM with 10% (v/v) heat-inactivated fetal calf
serum (FCS, Fisher scientific), 100 mg/ml (100 IU) penicillin/
streptomycin, and 2 mM L-glutamine on T75 ml flasks at 37uC at
5% CO2. At 80% confluency, cells were lifted using Accutase
(Sigma) and reseeded at a 1:10 ratio. For stimulation assays,
HaCaT cells were seeded into 12-well plates and at 50%
confluency, were stimulated for 24 hours with whole cell sonicated
M. leprae (supplied by Colorado State University) at 1 mg/ml,
10 mg/ml, 100 mg/ml or prednisolone (Sigma) at 1 nM, 10 nM, or
100 nM or 1 mM Pam3CSK4 (Toll-like receptor 2/1 ligand).
Assays were performed 3 times in triplicate.
To obtain primary human macrophages, peripheral blood
mononuclear cells (PBMCs) were first isolated from 50 ml whole
blood using a Ficoll gradient. PBMCs were cultured in RPMI with
10% FCS on a T75 flask for 24 hours at 37uC to allow monocyte
adherence. Nonadherent cells were gently removed with warm
media, adherent monocytes were washed with PBS and cultured
for 48 hours. Cells were lifted with Accutase, washed, and re-
cultured in 12 well plates for 48 hours at 10‘6 cells/ml.
Stimulation assays were performed as above. Assays were
performed 2 times in triplicate.
RNA isolation
After HaCaT and macrophage stimulation, RNA was isolated
using TRIzol Reagent (Invitrogen). According to manufacturer’s
instructions, 0.5 mg of total RNA was used for cDNA synthesis by
the iSCRIPT cDNA synthesis kit (Bio-Rad). For the skin biopsies,
RNA was isolated by first disrupting the skin using disposable
pestles and lysis buffer from the RNeasy Fibrous Tissue Mini Kit.
The skin was subjected to a Qiashredder (Qiagen) and RNA was
isolated using the RNeasy Fibrous Tissue Mini Kit (Qiagen) per
manufacturer’s instructions. RNA concentration was ascertained
using Nanodrop (ND-1000). RNA was converted to cDNA using
the Iscript kit (Invitrogen) per manufacturer’s instructions.
Real-time quantitative RT-PCR
Real-time quantitative RT-PCR was performed on an ABI
7900HT Fast Real-Time PCR (ABI) using Power SybrGreen
(ABI) and primers at a final concentration of 0.2 mM. The primer
sequences are as follows: 36B4 F: 59-TCGAACACCTGCTG-
GATGAC, 36B4 R: 59-CCACGCTGCTGAACATGCT, DEFB4
(hBD2) F: 59-GGTGTTTTTGGTGGTATAGGC, DEFB4
(hBD2) R: 59-AGGGCAAAAGACTGGATGACA, DEFB103
(hBD3) F: 59-GCTGCCTTCCAAAGGAGGA, DEFB103
(hBD3) R: 59-TTCTTCGGCAGCATTTTCG, TLR2 F: 59-
CATTCCCTCAGGGCTCACAG, TLR2 R: 59-TTGTTGGA-
CAGGTCAAGGCTT, TLR1 F: 59-GAGGCAATGCTGC-
TGTTCAG, TLR1 R: 59-CCTGGTACCCCTATTAGTGTT.
The DDCT method was used for quantification of gene expression.
The target genes were normalized to the endogenous reference
gene that encodes an acidic ribosomal phosphoprotein P0 (RPLP0)
also known as 36B4. Target genes are reported as the fold
difference relative to the reference gene. All of the stimulation
experiments were performed in triplicate and repeated at least two
times. All of the experiments using skin biopsies were analyzed by
real-time PCR in triplicate.
Immunoflorescence
HaCaT cells were seeded into chamber slides and stimulated at
50% confluency with 1 mM Pam3CSK4, 100 mg/ml M. leprae
whole cell sonicate, or 100 mg/ml prednisolone as indicated. After
24 hours, the supernatant was removed and cells were fixed with
acetone for 15 minutes at room temperature. The slides were
subsequently washed 3 times with 16 phosphate-buffered saline
(PBS), blocked for 1 hour at room temperature with 3% bovine
serum albumin in 16 PBS, and stained with primary antibodies
rabbit anti-hBD3 (Abcam) or rabbit IgG in 3% bovine serum
albumin/16PBS overnight at 4uC. After washing the cells 3 times
with PBS, the cells were stained with secondary antibodies goat
anti-rabbit IgG (Sigma), anti-rabbit IgG in 3% bovine serum
albumin in 16PBS for 1 hour at room temperature. Slides were
washed three times in 16 PBS and were mounted in ProLong
Anti-Fade reagent (Molecular Probes).
Statistical methods
All statistical analyses were performed using GraphPad Prism
4.0. An unpaired t-test was used when appropriate. Values of
p,0.05 were considered significant.
Results
Human beta-defensin 3 is up-regulated in cutaneous
leprosy type 1 reactions
To determine the levels of hBD2 and hBD3 expression in Type
1 reactions, the relative stable transcript levels were assessed in skin
biopsies of control leprosy patients and leprosy patients with Type
1 reactions. We found a trend towards increased hBD2 expression
in the skin of patients with Type 1 reactions by 16.6 fold-change,
though it was not statistically significant (p = 0.087) (Figure 1A).
Moreover, we found that hBD3 was significantly up-regulated in
the skin of patients with Type 1 reactions by 5.96 fold-change
(p,0.05) (Figure 1B).
Since T1Rs are clinically characterized by edema and
erythema, we investigated whether the increased hBD expression
was due to an increase in cellular infiltration. We found that the
cellularity score of the controls and T1Rs are similar (Figure 1C).
These data demonstrate that the increase in hBD2 and hBD3
expression is due to activation of the innate immune response
rather than due to an increase in the number hBD-expressing cells
in T1Rs.
Mycobacterium leprae induces human beta-defensins in
keratinocytes but not macrophages in vitro
Since the skin is comprised of multiple cell types that play a role
in cutaneous innate immunity, we sought to determine in which
cell type the hBDs are being up-regulated. Keratinocytes, the
primary cell in the epidermis, were first investigated for their
ability to up-regulate the hBDs in response to M. leprae. We found
that HaCaT cells, immortalized keratinocytes, increased their
expression of hBD2 and hBD3 in a dose-dependent manner in
response to M. leprae whole cell sonicate (Figure 2A and 2B). To
determine if macrophages induce a similar antimicrobial program
to HaCaT cells, primary macrophages were stimulated with M.
leprae whole cell sonicate at the indicated concentrations for
24 hours. We found that HaCaT cells but not macrophages up-
regulate hBD2 and hBD3 in response to M. leprae (Figure 2C and
2D). We also attempted to stain skin biopsies from patients with
Human Beta-Defensins in Leprosy Type 1 Reactions
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Type 1 reactions and from control leprosy patients with two
different anti-hBD3 antibodies. Unfortunately, both antibodies
exhibited non-specific staining and could not be used to assess the
temporal or relative quantity of hBD3 in the biopsies (data not
shown).
Since hBD production likely results from TLR2/1 activation by
M. leprae, we investigated whether TLR2 and TLR1 are induced in
M. leprae or TLR2/1 agonist (Pam3CSK4)-treated keratinocytes.
We found that M. leprae, as well as synthetic triacylated-lipopetide
Pam3CSK4, induce TLR2 but not TLR1 stable transcript levels
(Figure 3A and 3B). Taken together, these data demonstrate that
M. leprae activates keratinocytes through up-regulating the human
beta-defensins and TLR2 in vitro.
Corticosteroids suppress human beta-defensin
expression in the skin of patients with Type 1 reactions
To determine if oral corticosteroid treatment suppresses the
innate immune response in leprosy patients with Type 1
reactions, the expression of hBD2 and hBD3 was evaluated from
the skin of patients at day 0 and at day 113 of corticosteroid
treatment. For hBD2, we observe a mean relative transcript
suppression of 78.5% with 13/23 (56.5%) patients showing a
decrease in hBD2 expression (Figure 4A). For hBD3, we observe
a mean relative transcript suppression of 61.3% with 16/23
(69.6%) patients showing a decrease in hBD3 expression
(Figure 4B). In addition, 14 of the 23 patients with Type 1
reactions received an initial dose of intravenous methylprednis-
olone before a course of oral prednisolone. We found that
methylprednisolone caused no additional suppressive effect on
Figure 1. Human beta-defensin 3 is up-regulated in the skin of
leprosy patients with Type 1 reactions. Skin biopsies from leprosy
patients with Type 1 reactions (T1Rs) and leprosy patients without T1Rs
(Controls) were assessed for their expression hBD2 and hBD3 as
measured by qPCR. The skin of patients with T1Rs showed non-
significantly elevated (A) hBD2 expression and a significant increase in
(B) hBD3 expression. (C) Cellular infiltration in the T1Rs and the Controls
show no significant differences. For the statistical analyses, values were
first converted to a Gaussian distribution by taking their square and
subsequently an un-paired t-test was performed. *p,0.05 is considered
significant.
doi:10.1371/journal.pntd.0001869.g001
Figure 2. Mycobacterium leprae induces human beta-defensins 2
and 3 in keratinocytes but not macrophages. To determine
whether keratinocytes would induce an antimicrobial program to M.
leprae, immortalized keratinocytes (HaCaT cells) were stimulated with
M. leprae whole cell sonicate at 1 mg/ml, 10 mg/ml, 100 mg/ml for
24 hours. M. leprae induced a dose-dependent up-regulation of hBD2
(A) and hBD3 (B) stable transcript levels as measured by qPCR.
Macrophages cultured with M. leprae whole cell sonicate at 1 mg/ml,
10 mg/ml, 100 mg/ml for 24 hours showed no significant induction if
hBD2 (C) and hBD3 (D). Experiments were performed at least twice in
triplicate. **p,0.01, *p,0.05, n.s. (no significance) were determined by
an unpaired t-test when compared to the controls.
doi:10.1371/journal.pntd.0001869.g002
Figure 3. Mycobacterium leprae induces TLR2 but not TLR1 in
keratinocytes. Since activation of the TLR2/1 complex leads to
keratinocytes expression of hBD2 and hBD3, increase in TLR2 and/or
TLR1 may similarly lead to increased hBD expression. To evaluate
whether the expression of TLR2 and TLR1 are induced by M. leprae,
HaCaT cells were stimulated with 1 nM of the TLR2/1 agonist
Pam3CSK4 or 100 mg/ml M. leprae for 24 hours. Both Pam3CSK4 and
M. leprae significantly up-regulated stable transcript levels of (A) TLR2
but not (B) TLR1 in HaCaT cells. *p,0.05 or n.s. (no significance) were
determined by an unpaired t-test when compared to the controls.
doi:10.1371/journal.pntd.0001869.g003
Figure 4. Corticosteroids suppress human beta-defensins 2
and 3 in leprosy patients with Type 1 reactions. The expression of
hBD2 and hBD3 were assessed in skin biopsies of leprosy patients with
Type 1 reactions before (day 0) and after (day 113) corticosteroid
treatment. For hBD2, 13 out of 23 patients demonstrated suppression,
with a mean transcript suppression of 78.5% when comparing day 113
to day 0 (A). For hBD3, 16 out of 23 patients demonstrated suppression,
with a mean transcript suppression of 61.3% when comparing day 113
to day 0 (B).
doi:10.1371/journal.pntd.0001869.g004
Human Beta-Defensins in Leprosy Type 1 Reactions
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hBD2 and hBD3 and in fact, the two patient groups were nearly
identical in regards to their cutaneous suppression of hBD2 and
hBD3 (data not shown). Thus, all patients receiving corticosteroid
(prednisolone and methylprednisolone) were grouped together for
collective analyses (Figures 4A and 4B). These data illustrate that
oral corticosteroids suppress hBD2 and hBD3 in the skin of
patients with Type 1 reactions.
Keratinocyte induction of human beta-defensins by M.
leprae is suppressed by corticosteroids in vitro
We have demonstrated in Figure 2 that keratinocytes but not
macrophages up-regulate hBD2 and hBD3 in response to M. leprae
antigens, suggesting a role for the epidermidis in T1Rs. Since
corticosteroid treatment resulted in a suppression of the hBDs in
the skin of patients, we sought to determine if corticosteroids
would similarly result in the suppression of hBDs in cultured
keratinocytes. To determine if corticosteroids suppress keratino-
cyte innate immunity, HaCaT cells were stimulated in vitro with M.
leprae whole cell sonicate and an increasing dose of prednisolone.
We found that prednisolone significantly suppresses hBD2 and
hBD3 induction by M. leprae whole cell sonicate (Figure 5A and
5B). Suppression by prednisolone also appears to occur in a dose-
dependent manner (Figure 5A and 5B).
To confirm that prednisolone suppresses the protein levels of
hBD3 in keratinocytes, immunofluorescence was performed on
HaCaT cells. We found that the TLR2/1 L and M. leprae-treated
cells have an increase in intracellular hBD3 while prednisolone
reduces the intracellular level of hBD3 induced by M. leprae
(Figure 5C). Taken together, these data demonstrate that
prednisolone directly suppresses M. leprae-dependent hBD3 induc-
tion in keratinocytes.
Discussion
In this study, we have demonstrated that during Type 1
reactions, hBD3 is significantly up-regulated in the skin. This up-
regulation appears to be due to an increase in gene expression
rather than an increase in cellular infiltration (Figure 1). In
addition, we found that keratinocytes but not macrophages up-
regulate hBD2 and hBD3 in response to M. leprae in vitro. This
result was unanticipated since macrophages are known to play a
major role in leprosy pathogenesis. Moreover, we find it
interesting that keratinocytes were robustly responsive to M. leprae.
For these in vitro experiments, nonviable, sonicated M. leprae was
employed. While the possibility cannot be ruled out that live
infection may generate immune variation, leprosy reactions
appear to occur or persist regardless of M. leprae viability [28].
In addition, most patients receiving corticosteroids for leprosy
reactions are concurrently receiving MDT or have completed
MDT, rendering M. leprae essentially nonviable within the study
time period [29]. Yet, in the future, viable M. leprae could be useful
to assess the host response during an active infection.
Few previous studies have suggested that the epidermis plays a
role in leprosy or reactions, in spite of the cutaneous manifesta-
tions. This may be attributed to the fact that keratinocytes are
often thought of as part of the barrier rather than as an immune
organ. In fact, keratinocytes play a significant role in immune
homeostasis and innate immunity. Our data demonstrating that
HaCaTs up-regulated TLR2 in response to M. leprae suggests that
the cells are preparing to respond to pathogens. The downstream
effect of increased TLR2 expression would likely lead to an
enhanced ability to sense lipo-polypeptides and subsequent up-
regulation of antimicrobial peptides.
There have been a number of important studies on the cytokine
milieu in leprosy [2,30]. It has also been demonstrated that
proinflammatory cytokines induce the expression of antimicrobial
peptides in gingival keratinocytes [31]. It is possible that the
cytokine environment is causing an induction of hBDs, rather than
direct mycobacterial interaction with keratinocytes. Yet, myco-
bacterial lipids are known to directly induce TLR-mediated
antimicrobial responses. For leprosy, electron microscopy studies
demonstrating M. leprae inhabitance in keratinocytes further
suggest a direct interaction. Finally, recent studies on cutaneous
microbiota demonstrate that an intricate relationship exists
between bacterium and keratinocytes [32,33,34]. In the future, it
would be interesting to elucidate the specific cellular and
molecular interactions between keratinocytes and M. leprae.
The effects of steroids on the expression of hBDs were not
surprising, yet we included these studies to correlate the hBD
expression with T1Rs. Corticosteroids that bind the glucocorticoid
receptor have been shown to suppress the expression of
proinflammatory cytokines through NFkB [35]. Toll-like receptor
2 initially signals through MyD88 and IRAK, subsequently
leading to NFkB activation and production of hBDs [36]. Thus,
TLR2-mediated suppression of hBDs by steroids is expected but
also confirms that steroids directly affect the dermis and epidermis.
It would be interesting to determine the status of keratinocytes in
the skin of patients with T1Rs in the presence and the absence of
steroids. These studies would further clarify the relative impor-
tance of keratinocytes in T1Rs.
Based on our data, we hypothesize that the epidermis plays a
more substantial role than previously thought. Many studies have
demonstrated that keratinocytes can kill bacteria, viruses, fungi,
and parasites through the production of antimicrobial peptides.
We hypothesize that the up-regulation of hBDs in keratinocytes
leads to reduction of M. leprae during Type 1 reactions for several
Figure 5. Prednisolone suppresses keratinocyte up-regulation
of human beta-defensins 2 and 3 by M. leprae in vitro. To
determine whether prednisone suppresses keratinocyte expression of
hBD2 and hBD3, HaCaT cells were stimulated with 100 mg/ml M. leprae
and 0 (Control), 1, 10, and 100 nM of prednisone for 24 hours.
Prednisolone caused a dose-dependent suppression hBD2 (A) and hBD3
(B). To confirm the suppression of hBD3 by prednisolone on the protein
level, HaCaT cells were cultured in chamber slides with media alone
(Control), 1 nM Pam3CSK4, 100 mg/ml M. leprae, or 100 mg/ml M. leprae
and 100 nM prednisolone. Strong intracellular hBD3 expression is
observed in cells treated with Pam3CSK4 or M. leprae. Prednisolone
reduces the level of intracellular hBD3 produced by HaCaTs in response
to M. leprae (C). IgG controls are represented by the bottom panel
images. Significance (*p,0.05) was determined by an unpaired t-test.
doi:10.1371/journal.pntd.0001869.g005
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reasons. First, since the hBDs are directly antimicrobial, they may
directly kill the M. leprae living in the keratinocytes or may be
secreted and kill the bacteria in the upper papillary dermis near
the basement membrane. Unfortunately, as we are currently
unable to grow M. leprae in vitro, we are consequently not able to
conclusively test the antimicrobial role of the hBDs without a
mouse footpad or an armadillo model of infection. Another means
by which the hBDs may lead to the reduction of M. leprae, which
occurs during Type 1 reactions, is due to their pro-inflammatory
potential. If the basal keratinocytes release the hBDs into the
dermis, they may activate dermal macrophages, subsequently
leading to cytokine production and an antimicrobial response. An
increase in Th1 cytokines will activate macrophages, leading to a
further reduction of M. leprae. It would be interesting to determine
whether defensins promote the differentiation of macrophages in
Type 1 reactions.
Additional experiments, such as immunohistochemistry of skin
sections for the hBDs and TLR2 knockdown experiments, would
be useful to more conclusively demonstrate mechanisms by which
the innate immune system is activated.
In conclusion, we show that hBD3 is upregulated in leprosy
Type 1 reactions. Elucidating the means by which keratinocytes
interact with M. leprae and cells in the dermis will shed light on
future diagnostics, host-pathogen interplay, and mechanisms of
infection.
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